AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher

Traders Union
All News
Stocks
AbbVie slips 2.01% this week

Highlights

Shares of AbbVie fell 2.01% over the past week to $288.94, but maintain a bullish long-term structure.
Weekly volatility is measured at 5.99%, and momentum indicators suggest potential for further upside despite recent weakness.
The stock is expected to trade in a range of $281.39 to $302.5, with 77% probability of an increase and nearest resistance at $298.5.

Improved guidance and drug updates lift outlook after strong quarterly results

AbbVie reported third-quarter 2026 financial results with revenue of $17.4 billion, an operational increase of 10.5%, and adjusted diluted EPS of $3.82, both more than double year over year, according to PR Newswire. The company raised its full-year 2026 revenue guidance to $67.8 billion and increased its quarterly dividend by 5.2% to $1.82 per share, effective with the February 2027 payment, as reported by Yahoo Finance. AbbVie also highlighted strong performance from its immunology drugs Skyrizi and Rinvoq, as well as positive updates on its combination therapy for Crohn’s disease and the acquisition of Apogee to boost its late-stage pipeline.

Upside bias holds as MACD and ADX strengthen despite short-term divergence

The daily chart shows a trending setup, with momentum characterized by a sustained move lower and a firm trend amid 5.99% weekly volatility. MACD and ADX both favor further upside, while level-based oscillators such as RSI (63.45) and CCI are in neutral zones, though Stochastic RSI is in its oversold zone, pointing to potential divergence in short-term momentum. Nearest support sits at $282.84 (20-day MA), while resistance stands at $298.5, with the Ichimoku Kijun at $278.4 acting as additional support.

Consolidation likely with breakout risk around resistance in the coming week

In the week ahead, AbbVie is expected to trade within a range of $281.39 to $302.5. There is a 77% probability of an increase and a 23% chance of a decrease. The base case calls for consolidation or further trend development between $282.84 support and $298.5 resistance. A break above $298.5 would open the way for further gains toward the upper end of the expected range, while a move below $282.84 could trigger additional downside toward $281.39 or the Ichimoku support at $278.4.

Anton Kharitonov, expert at Traders Union, notes that shares of AbbVie are trading near $289 following a 2% dip this week. Despite the pullback, buyers remain in control as the stock holds its recent gains. AbbVie's upbeat corporate results, with revenue and EPS more than doubling year over year and a boosted dividend, provide a steady fundamental backdrop. The daily technical setup shows momentum indicators (MACD, ADX) favoring further upside, but oscillators like RSI and CCI remain neutral while the Stochastic RSI sits in oversold territory, hinting at possible near-term divergence. He expects shares to consolidate between $282.84 support and $298.5 resistance in the coming week, with downside risks if $282.84 fails. "Unless AbbVie stock breaks above $298.5 convincingly, I remain cautious and prioritize risk management around key support levels this week."

Earlier, analysts noted that AbbVie's underlying technical trend remained constructive despite mixed momentum readings and persistent equity market volatility. The current setup introduces a potential inflection point, with traders advised to monitor the $298.5 resistance level for confirmation of renewed upside momentum.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.